Plasminogen activator inhibitor-1 polymorphisms (?44 G>A and HindIII C>G) in systemic lupus erythematosus: association with clinical variables
详细信息 查看全文
- 作者：Jorge Ramón Padilla-Gutiérrez (1) (2)
Claudia Azucena Palafox-Sánchez (1)
Yeminia Valle (1) (2)
Gerardo Orozco-Barocio (3)
Edith Oregón-Romero (1)
Mónica Vázquez-Del Mercado (1)
Héctor Rangel-Villalobos (4)
Mara Anaís Llamas-Covarrubias (1)
José Francisco Mu?oz-Valle (1) - 关键词：PAI ; 1 ; Polymorphisms ; Haplotypes ; SLE
- 刊名：Clinical and Experimental Medicine
- 出版年：2011
- 出版时间：March 2011
- 年：2011
- 卷：11
- 期：1
- 页码：11-17
- 全文大小：224KB
- 参考文献：1. Petri M (2006) Systemic lupus erythematosus: 2006 update. J Clin Rheumatol 12:37-0 CrossRef
2. Edberg JC, Wu J, Langefeld CD, Brown EE, Marion MC, McGwin G Jr, Petri M, Ramsey-Goldman R, Reveille JD, Frank SG, Kaufman KM, Harley JB, Alarcón GS, Kimberly RP (2008) Genetic variation in the CRP promoter: association with systemic lupus erythematosus. Hum Mol Genet 17:1147-155 CrossRef
3. Fernández M, Alarcón G, Calvo-Alén J, Andrade R, McGwin G Jr, Vilá LM, Reveille JD, LUMINA Study Group (2007) A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum 57:576-84 CrossRef
4. Palafox-Sánchez CA, Vázquez-Del Mercado M, Orozco-Barocio G, Torre IG, Torres-Carrillo N, Torres-Carrillo NM, Illades-Aguiar B, Mu?oz Valle JF (2009) A functional Ser413/Ser413 PAI-2 polymorphism is associated with susceptibility and damage index score in systemic lupus erythematosus. Clin Appl Thromb Hemost 15:233-38 CrossRef
5. Wang AY, Ponn P, Lai FM, Yu L, Choi PC, Lui SF, Li PK (2001) Plasminogen activator inhibitor-1 gene polymorphism 4G/4G genotype and lupus nephritis in Chinese patients. Kidney Int 59:1520-528 CrossRef
6. Tassies D, Espinosa G, Mu?oz-Rodriguez FJ, Freire C, Cervera R, Monteagudo J, Maragall S, Escolar G, Ingelmo M, Ordinas A, Font J, Reverter JC (2000) The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. Arthritis Rheum 43:2349-358 CrossRef
7. Huber K (2001) Plasminogen activator inhibitor type-1 (Part One): basic mechanisms, regulation, and role for thromboembolic disease. J Thromb Thrombolysis 11:183-93 CrossRef
8. Gils A, Declerck PJ (2004) Plasminogen activator inhibitor-1. Curr Med Chem 11:2323-334
9. Binder BR, Christ G, Gruber F, Grubic N, Hufnagl P, Krebs M, Mihaly J, Prager GW (2002) Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News Physiol Sci 17:56-1
10. Morange PE, Henry M, Tregou?t B, Granel B, Aillaud MF, Alessi MC, Juhan-Vague I (2000) The A -844G polymorphism in the PAI-1 gene is associated with a higher risk of venous thrombosis in Factor V Leiden carriers. Arterioscler Thromb Vasc Biol 20:1387-391
11. Adamski MG, Turaj W, Slowik A, Wloch-Kopec D, Wolkow P, Szczudlik A (2009) A-G-4G haplotype of PAI-1 gene polymorphisms -844 G/A, / HindIII G/C, and -675 4G/5G is associated with increased risk of ischemic stroke caused by small vessel disease. Acta Neurol Scand 120:94-00 CrossRef
12. Sejima T, Madoiwa S, Mimuro J, Sugo T, Okada K, Ueshima S, Matsuo O, Ishida T, Ichimura K, Sakata Y (2005) Protection of plasminogen activator inhibitor-1-deficient mice from nasal allergy. J Immunol 174:8135-143
13. Renckens R, Pater JM, van der Poll T (2006) Plasminogen activator inhibitor type-1-deficient mice have enhanced IFN-g response to lipopolysaccharide and staphylococcal enterotoxin B. J Immunol 177:8171-176
14. Hirankarn N, Tangwattanachuleeporn M, Wongpiyabovorn J, Wongchinsri J, Avihingsanon Y (2009) Association of IL-18 gene polymorphism (?37C) with arthritis manifestations in SLE: combined effect with IFN gamma gene polymorphism (+874A). Clin Rheumatol 28:219-23 CrossRef
15. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215 CrossRef
16. Zaykin D, Zhivotovsky L, Weir BS (1995) Exact test for association between alleles at arbitrary numbers of loci. Genetic 96:169-78. [GDA program]. Version 1.1
17. Excoffier L, Staltkin M (1995) Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 12:921-27
18. Criswell LA (2008) The genetic contribution to systemic lupus erythematosus. Bull NYU Hosp Jt Dis 66:176-83
19. Pullmann R Jr, Bonilla E, Phillips PE, Middleton FA, Perl A (2008) Haplotypes of the HRES-1 endogenous retrovirus are associated with development and disease manifestations of systemic lupus erythematosus. Arthritis Rheum 58:532-40 CrossRef
20. Christiansen FT, Zhang WJ, Griffiths M, Mallal SA, Dawkins RL (1991) Major histocompatibility complex (MHC) complement deficiency, ancestral haplotypes and systemic lupus erythematosus (SLE): C4 deficiency explains some but not all of the influence of the MHC. J Rheumatol 18:1350-358
21. Duits AJ, Bootsma H, Derksen RH, Spronk PE, Kater L, Kallenberg CG, Capel PJ, Westerdaal NA, Spierenburg GT, Gmelig-Meyling FH et al (1995) Skewed distribution of IgG Fc receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. Arthritis Rheum 38:1832-836 CrossRef
22. Sullivan KE, Jawad AF, Piliero LM, Kim N, Luan X, Goldman D, Petri M (2003) Analysis of polymorphisms affecting immune complex handling in systemic lupus erythematosus. Rheumatology (Oxford) 42:446-52 CrossRef
23. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW, Ortmann WA, Koeuth T, González Escribano MF, Argentine and Spanish Collaborative Groups, Pons-Estel B, Petri M, Daly M, Gregersen PK, Martín J, Altshuler D, Behrens TW, Alarcón-Riquelme ME (2006) A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 38:550-55 CrossRef
24. Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW, de Bakker PI, Le JM, Lee HS, Batliwalla F, Li W, Masters SL, Booty MG, Carulli JP, Padyukov L, Alfredsson L, Klareskog L, Chen WV, Amos CI, Criswell LA, Seldin MF, Kastner DL, Gregersen PK (2007) STAT4 and the risk of rheumatoid artritis and systemic lupus erythematosus. N Engl J Med 357:977-86 CrossRef
25. Hom G, Graham RR, Modrek B, Taylor KE, Ortmann W, Garnier S, Lee AT, Chung SA, Ferreira RC, Pant PV, Ballinger DG, Kosoy R, Demirci FY, Kamboh MI, Kao AH, Tian C, Gunnarsson I, Bengtsson AA, Rantap??-Dahlqvist S, Petri M, Manzi S, Seldin MF, R?nnblom L, Syv?nen AC, Criswell LA, Gregersen PK, Behrens TW (2008) Association of systemic lupus erythematosus with C8orf13–BLK and ITGAM–ITGAX. N Engl J Med 358:900-09 CrossRef
26. Gong R, Liu Z, Li L (2007) Epistatic effect of plasminogen activator inhibitor 1 and beta-fibrinogen genes on risk of glomerular microthrombosis in lupus nephritis: interaction with environmental/clinical factors. Arthritis Rheum 56:1608-617 CrossRef
27. Akey J, Jin L, Xiong M (2001) Haplotypes vs single marker linkage disequilibrium tests: what do we gain? Eur J Hum Genet 9:291-00 CrossRef
28. Henry M, Chomiki N, Scarabin PY, Alessi MC, Peiretti F, Arveiler D, Ferrières J, Evans A, Amouyel P, Poirier O, Cambien F, Juhan-Vague I (1997) Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. Arterioscler Thromb Vasc Biol 17:851-58
29. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S (1991) Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 11:183-90
30. Torres-Carrillo N, Magdalena Torres-Carrillo N, Vázquez-Del Mercado M, Rangel-Villalobos H, Parra-Rojas I, Sánchez-Enríquez S, Mu?oz-Valle JF (2008) Distribution of -844 G/A and / HindIII C/G PAI-1 polymorphisms and plasma PAI-1 levels in Mexican subjects: comparison of frequencies between populations. Clin Appl Thromb Hemost 14:220-26 CrossRef
31. Su S, Chen S, Zhao J, Huang J, Wang X, Chen R, Gu D (2006) Plasminogen activator inhibitor-1 gene: selection of tagging single nucleotide polymorphisms and association with coronary heart disease. Arterioscler Thromb Vasc Biol 26:948-54 CrossRef
32. Alba P, Bento L, Cuadrado MJ, Karim Y, Tungekar MF, Abbs I, Khamashta MA, D’Cruz D, Hughes GR (2003) Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann Rheum Dis 62:556-60 CrossRef
33. Chen JY, Wang CM, Ma CC, Luo SF, Edberg JC, Kimberly RP, Wu J (2006) Association of a transmembrane polymorphism of Fcgamma receptor IIb (FCGR2B) with systemic lupus erythematosus in Taiwanese patients. Arthritis Rheum 54:3908-917 CrossRef
34. Fritzler MJ, Wiik A, Tan EM, Smolen JS, McDougal JS, Chan EK, Gordon TP, Hardin JA, Kalden JR, Lahita RG, Maini RN, Reeves WH, Rothfield NF, Takasaki Y, Wilson M, Byrd MG, Slivka L, Koziol JA (2003) A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. J Rheumatol 30:2374-381
35. Torres-Carrillo N, Torres-Carrillo NM, Martínez-Bonilla GE, Vázquez-Del Mercado M, Palafox-Sánchez CA, Oregón-Romero E, Bernard-Medina AG, Rangel-Villalobos H, Mu?oz-Valle JF (2009) Plasminogen activator inhibitor-1 C/G polymorphism in relation to plasma levels in rheumatoid arthritis. Clin Exp Med 9:223-28 CrossRef - 作者单位：Jorge Ramón Padilla-Gutiérrez (1) (2)
Claudia Azucena Palafox-Sánchez (1)
Yeminia Valle (1) (2)
Gerardo Orozco-Barocio (3)
Edith Oregón-Romero (1)
Mónica Vázquez-Del Mercado (1)
Héctor Rangel-Villalobos (4)
Mara Anaís Llamas-Covarrubias (1)
José Francisco Mu?oz-Valle (1)
1. Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Insurgentes 244-1, Colonia Lomas de Atemajac, 45178, Zapopan, Jalisco, México
2. Posdoctoral Fellow in Biomedical Sciences (Immunology). Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, México
3. Departamento de Inmunología y Reumatología del Hospital General de Occidente, Secretaría de Salud Jalisco, Av. Zoquipan 1050, 45100, Zapopan, Jalisco, México
4. Instituto de Investigación en Genética Molecular, Centro Universitario de la Ciénega, Universidad de Guadalajara, Ocotlán, Jalisco, México
文摘
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by the presence of autoantibodies against nuclear autoantigens as well as cytoplasmic and circulating proteins. Recent studies have demonstrated mechanisms responsible for modulation of the immune response by the plasminogen activator inhibitor-1 (PAI-1). Furthermore, the endogenous PAI-1 has shown to promote a Th2 immune response. We assessed the ?44 G>A and HindIII C>G PAI-1 polymorphisms in SLE. In a case–control study of 71 SLE patients classified according to ACR criteria and 71 healthy subjects (HS). The A allele of ?44 PAI-1 polymorphism showed a significant difference in SLE patients (41%) when compared with HS (27%) [P?=?0.01; OR?=?1.8, 95%, CI?=?1.1-.0]. In addition, the ?44 G>A PAI-1 polymorphism was associated with increased risk for SLE in a dominant genetic model (G/G vs. G/A?+?A/A; OR?=?2.3, 95% CI?=?1.14-.44). Also, anti-RNP positive antibodies in SLE were associated with G/G ?44 PAI-1 genotype. The HindIII polymorphism did not show any differences. The haplotype analysis showed that the AC haplotype confers susceptibility to SLE (OR?=?3.1, 95% CI, 1.45-.52; P?=?0.003). The AC haplotype of the ?44 and HindIII PAI-1 polymorphism might be an additional susceptibility factor to SLE in Mexicans.